150 related articles for article (PubMed ID: 15515777)
1. Serum soluble CD30 levels in Behçet's disease.
Düzgün N; Ayaslioglu E; Tutkak H
Clin Exp Rheumatol; 2004; 22(4 Suppl 34):S17-20. PubMed ID: 15515777
[TBL] [Abstract][Full Text] [Related]
2. Vitamin D modulates peripheral immunity in patients with Behçet's disease.
Hamzaoui K; Ben Dhifallah I; Karray E; Sassi FH; Hamzaoui A
Clin Exp Rheumatol; 2010; 28(4 Suppl 60):S50-7. PubMed ID: 20868571
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor necrosis factor-alpha response in rheumatoid arthritis is associated with an increase in serum soluble CD30.
Gerli R; Lunardi C; Bocci EB; Bobbio-Pallavicini F; Schillaci G; Caporali R; Bistoni O; Pirro M; Pitzalis C; Montecucco C
J Rheumatol; 2008 Jan; 35(1):14-9. PubMed ID: 18061981
[TBL] [Abstract][Full Text] [Related]
4. Th1 polarization of the immune response in uveitis in Behçet's disease.
Ilhan F; Demir T; Türkçüoğlu P; Turgut B; Demir N; Gödekmerdan A
Can J Ophthalmol; 2008 Feb; 43(1):105-8. PubMed ID: 18204495
[TBL] [Abstract][Full Text] [Related]
5. Serum MMP-2 and MMP-9 in patients with Behçet's disease: do their higher levels correlate to vasculo-Behçet's disease associated with aneurysm formation?
Pay S; Abbasov T; Erdem H; Musabak U; Simsek I; Pekel A; Akdogan A; Sengul A; Dinc A
Clin Exp Rheumatol; 2007; 25(4 Suppl 45):S70-5. PubMed ID: 17949555
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of soluble CD30 in patients with atopic dermatitis: correlations with age, disease duration and severity.
El Mongy S; Metwaly SS; Arafat MS; Hady HA
Egypt J Immunol; 2008; 15(1):123-9. PubMed ID: 20306677
[TBL] [Abstract][Full Text] [Related]
7. Passage from normal mucosa to adenoma and colon cancer: alteration of normal sCD30 mechanisms regulating TH1/TH2 cell functions.
Contasta I; Berghella AM; Pellegrini P; Adorno D
Cancer Biother Radiopharm; 2003 Aug; 18(4):549-57. PubMed ID: 14503949
[TBL] [Abstract][Full Text] [Related]
8. Soluble CD30 serum levels in atopic dermatitis and bronchial asthma and its relationship with disease severity in pediatric age.
Heshmat NM; El-Hadidi ES
Pediatr Allergy Immunol; 2006 Jun; 17(4):297-303. PubMed ID: 16771784
[TBL] [Abstract][Full Text] [Related]
9. Effect of fluticasone propionate on soluble CD30 release in patients with severe allergic asthma.
Purello-D'Ambrosio F; Gangemi S; Ruello G; Marotta G; Merendino RA
J Investig Allergol Clin Immunol; 2000; 10(5):283-5. PubMed ID: 11108439
[TBL] [Abstract][Full Text] [Related]
10. Circulating soluble-CD30 (sCD30) in patients with HCV-related chronic hepatitis and in patients with alcoholic liver disease.
De Lazzari F; Ravagnan P; Tenderini M; Vicarioto MA; Galliani EA; Lorenzoni U; Popovic A; Floreani A
Hepatogastroenterology; 2002; 49(43):231-4. PubMed ID: 11941962
[TBL] [Abstract][Full Text] [Related]
11. Circulating soluble CD28 in patients with Behçet's disease: relationship to clinical manifestations.
Hamzaoui K; Hamzaoui A; Bouajina L; Houman H
Clin Exp Rheumatol; 2005; 23(4 Suppl 38):S49-52. PubMed ID: 16273764
[TBL] [Abstract][Full Text] [Related]
12. Soluble CD30 serum level--an adequate marker for allograft rejection of solid organs?
Schlaf G; Altermann WW; Rothhoff A; Seliger B
Histol Histopathol; 2007 Nov; 22(11):1269-79. PubMed ID: 17647199
[TBL] [Abstract][Full Text] [Related]
13. Imbalance of Th17 to Th1 cells in Behçet's disease.
Kim J; Park JA; Lee EY; Lee YJ; Song YW; Lee EB
Clin Exp Rheumatol; 2010; 28(4 Suppl 60):S16-9. PubMed ID: 20868565
[TBL] [Abstract][Full Text] [Related]
14. Serum galectin-3 and galectin-3 binding protein levels in Behçet's disease and their association with disease activity.
Lee YJ; Kang SW; Song JK; Park JJ; Bae YD; Lee EY; Lee EB; Song YW
Clin Exp Rheumatol; 2007; 25(4 Suppl 45):S41-5. PubMed ID: 17949550
[TBL] [Abstract][Full Text] [Related]
15. CD30 cell expression and abnormal soluble CD30 serum accumulation in Omenn's syndrome: evidence for a T helper 2-mediated condition.
Chilosi M; Facchetti F; Notarangelo LD; Romagnani S; Del Prete G; Almerigogna F; De Carli M; Pizzolo G
Eur J Immunol; 1996 Feb; 26(2):329-34. PubMed ID: 8617299
[TBL] [Abstract][Full Text] [Related]
16. Plasma sCD26 and sCD30 levels in cutaneous leishmaniasis.
Jafari-Shakib R; Shokrgozar MA; Nassiri-Kashani M; Malakafzali B; Nikbin B; Khamesipour A
Acta Trop; 2009 Jan; 109(1):61-3. PubMed ID: 18983807
[TBL] [Abstract][Full Text] [Related]
17. Association of CD30 transcripts with Th1 responses and proinflammatory cytokines in patients with end-stage renal disease.
Velásquez SY; Opelz G; Rojas M; Süsal C; Alvarez CM
Hum Immunol; 2016 May; 77(5):403-10. PubMed ID: 26970513
[TBL] [Abstract][Full Text] [Related]
18. Serum soluble CD30 in early arthritis: a sign of inflammation but not a predictor of outcome.
Savolainen E; Matinlauri I; Kautiainen H; Luosujärvi R; Kaipiainen-Seppänen O
Clin Exp Rheumatol; 2008; 26(5):922-5. PubMed ID: 19032830
[TBL] [Abstract][Full Text] [Related]
19. The expression of transmembrane and soluble CXCL16 and the relation with interferon-alpha secretion in patients with Behçet's disease.
Yilmaz S; Cinar M; Pekel A; Simsek I; Musabak U; Erdem H; Pay S
Clin Exp Rheumatol; 2013; 31(3 Suppl 77):84-7. PubMed ID: 24064021
[TBL] [Abstract][Full Text] [Related]
20. Soluble CD30 in normal pregnancy, pre-eclampsia and recurrent pregnancy loss.
Gharesi-Fard B; Jafarzadeh L; Zolghadri J; Haghbin H
Iran J Immunol; 2012 Dec; 9(4):234-40. PubMed ID: 23268289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
